Table 3.

Effect of SGLT-2 inhibitors on weight loss in people with and without T2D

Drug	Approval (year)	Weight loss in people with diabetes	Weight loss in people without diabetes
Dapagliflozin	EMA (2012); FDA (2014)	3.2 kg over 24 weeks [58]	Dapagliflozin: 3.0 kg (12 weeks) [59] Dapagliflozin + exenatide: 5.7 kg (52 weeks) [61]
Canagliflozin	EMA (2013); FDA (2013)	2.5–4.0 kg [63, 64]	Canagliflozin: 1.9 kg (50 mg); 2.8 kg (100 mg) and 2.4 kg (300 mg) [65]
Empagliflozin	EMA (2014); FDA (2014)	2.1–2.5 kg over 24–104 weeks [67, 68]	None
Ertugliflozin	EMA (2018); FDA (2017)	2.7–3.7 kg over 52 weeks [69, 70]	None

Presents the observed weight loss with each of the approved SGLT-2 inhibitors in people with and without T2D